By background I am an investment professional who did Australian equity research from the late 1990s until early 2015 and again from mid-2016. For a lot of the time I have worked as an analyst I focused on healthcare and biotechnology, and the Life Sciences has become a passion of mine. My forte is making complex, technology-based investment ideas easy to understand. In January 2015 I joined my first biotechnology company, a cancer immunotherapy play called Prima Biomed (Nasdaq: PBMD) and had a great time with them until November 2015. From January until May 2016 I took care of investor relations for another cancer immunotherapy company, Imugene (ASX: IMU). In June 2016 I returned to the equities analyst game with the founding of NDF Research. Two years later in June 2018 I teamed up with Marc Kennis to found Pitt Street Research with the aim of providing issuer-sponsored equity research to the entire spectrum of ASX-listed companies. Please note that any advice given by NDF Research or Pitt Street Research is GENERAL advice.
ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
We value your privacy
We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy